ReviewPharmaceuticals (Basel, Switzerland)2023
An Insight into Advances in Developing Nanotechnology Based Therapeutics, Drug Delivery, Diagnostics and Vaccines: Multidimensional Applications in Tuberculosis Disease Management.
Review in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 39 citations in OpenAlex.
- Advancing Tuberculosis Chemotherapy: Targeted Nanomedicines for the Mycobacterium TB Granuloma.Small (Weinheim an der Bergstrasse, Germany) · 2025Review
- Application of nanoparticles in the treatment of acute lung injury: Current situation and future directions.Materials today. Bio · 2025Review
- Gut microbiota and tuberculosis.iMeta · 2025Review
- Steady Shear Rheology of Suspensions of Mixtures of Starch Nanoparticles and Cellulose Nanocrystals.Nanomaterials (Basel, Switzerland) · 2025Article
- A temperature-responsive PLA-based nanosponge as a novel nanoadjuvant and efficient delivery carrier of Ag85B for effective vaccine against Mycobacterium tuberculosis.Cell communication and signaling : CCS · 2025Article
- Advancing against drug-resistant tuberculosis: an extensive review, novel strategies and patent landscape.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Strategies in Taxol Development: A Review.Mini reviews in medicinal chemistry · 2025Review
- Role of Nanoformulations in the Treatment of Lung Cancer.Recent patents on nanotechnology · 2025Review
- Progress in the role of nanoparticles in the diagnosis and treatment of bone and joint tuberculosis.Frontiers in medicine · 2025Review
- Enhancing Drug Solubility, Bioavailability, and Targeted Therapeutic Applications through Magnetic Nanoparticles.Molecules (Basel, Switzerland) · 2024Review
- Biosensors; nanomaterial-based methods in diagnosing ofJournal of clinical tuberculosis and other mycobacterial diseases · 2024Review
- Nanotechnology-based approaches for targeted drug delivery for the treatment of respiratory tract infections.Journal of biological methods · 2024Review
- Ending tuberculosis: challenges and opportunities.Frontiers in tuberculosis · 2024Review
- Analysis of Nanoparticles' Effects on Drug-Induced Psoriasis.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Nanocarriers in Tuberculosis Treatment: Challenges and Delivery Strategies.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Combined System for the Simultaneous Delivery of Levofloxacin and Rifampicin: Structural and Functional Properties and Antibacterial Activity.Journal of functional biomaterials · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 10 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberculosis (TB), one of the deadliest contagious diseases, is a major concern worldwide. Long-term treatment, a high pill burden, limited compliance, and strict administration schedules are all variables that contribute to the development of MDR and XDR tuberculosis patients. The rise of multidrug-resistant strains and a scarcity of anti-TB medications pose a threat to TB control in the future. As a result, a strong and effective system is required to overcome technological limitations and improve the efficacy of therapeutic medications, which is still a huge problem for pharmacological technology. Nanotechnology offers an interesting opportunity for accurate identification of mycobacterial strains and improved medication treatment possibilities for tuberculosis. Nano medicine in tuberculosis is an emerging research field that provides the possibility of efficient medication delivery using nanoparticles and a decrease in drug dosages and adverse effects to boost patient compliance with therapy and recovery. Due to their fascinating characteristics, this strategy is useful in overcoming the abnormalities associated with traditional therapy and leads to some optimization of the therapeutic impact. It also decreases the dosing frequency and eliminates the problem of low compliance. To develop modern diagnosis techniques, upgraded treatment, and possible prevention of tuberculosis, the nanoparticle-based tests have demonstrated considerable advances. The literature search was conducted using Scopus, PubMed, Google Scholar, and Elsevier databases only. This article examines the possibility of employing nanotechnology for TB diagnosis, nanotechnology-based medicine delivery systems, and prevention for the successful elimination of TB illnesses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.